Patients are often stabilised for years on somatostatin analogues; however, progression eventually necessitates disease‑controlling therapy. Clinically, the somatostatin receptor subtype 2 (SSTR2) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback